LLY · Company KPIs
Eli Lilly (LLY) KPIs
Mounjaro revenue, Zepbound revenue, Revenue volume change. As reported in SEC filings, with the source line for each figure.
Mounjaro revenue
$10.72B for the period ended Sep 30, 2026
The filings read for this page do not define this measure.
| Period ended | Figure | Filing text |
|---|---|---|
| Sep 30, 2026 | $10.72B | Mounjaro · $10,723 · $6,515 · 65% · $29,328 · $15,556 · 89%8-K filed 2026-10-29 |
| Jun 30, 2026 | $9.94B | Mounjaro · $9,943 · $5,199 · 91% · $18,605 · $9,041 · 106%8-K filed 2026-08-05 |
| Mar 31, 2026 | $8.66B | Mounjaro · $8,662 · $3,842 · 125%8-K filed 2026-04-30 |
| Dec 31, 2025 | $7.41B | Mounjaro · $7,409 · $3,530 · 110% · $22,965 · $11,540 · 99%8-K filed 2026-02-04 |
| Sep 30, 2025 | $6.52B | Mounjaro · $6,515.1 · $3,112.7 · 109% · $15,555.8 · $8,010.0 · 94%8-K filed 2025-10-30 |
| Jun 30, 2025 | $5.2B | Mounjaro · $9,943 · $5,199 · 91% · $18,605 · $9,041 · 106%8-K filed 2026-08-05 |
| Mar 31, 2025 | $3.84B | Mounjaro · $8,662 · $3,842 · 125%8-K filed 2026-04-30 |
| Dec 31, 2024 | $3.53B | Mounjaro · $7,409 · $3,530 · 110% · $22,965 · $11,540 · 99%8-K filed 2026-02-04 |
Zepbound revenue
$5.35B for the period ended Sep 30, 2026
The filings read for this page do not define this measure.
| Period ended | Figure | Filing text |
|---|---|---|
| Sep 30, 2026 | $5.35B | Zepbound(1) · 5,352 · 3,588 · 49% · 14,440 · 9,281 · 56%8-K filed 2026-10-29 |
| Jun 30, 2026 | $4.93B | Zepbound(1) · 4,928 · 3,381 · 46% · 9,088 · 5,693 · 60%8-K filed 2026-08-05 |
| Mar 31, 2026 | $4.16B | Zepbound(1) · 4,160 · 2,312 · 80%8-K filed 2026-04-30 |
| Dec 31, 2025 | $4.26B | Zepbound(1) · 4,261 · 1,907 · 123% · 13,542 · 4,926 · 175%8-K filed 2026-02-04 |
| Sep 30, 2025 | $3.59B | Zepbound · 3,588.1 · 1,257.8 · 185% · 9,281.3 · 3,018.4 · NM8-K filed 2025-10-30 |
| Jun 30, 2025 | $3.38B | Zepbound(1) · 4,928 · 3,381 · 46% · 9,088 · 5,693 · 60%8-K filed 2026-08-05 |
| Mar 31, 2025 | $2.31B | Zepbound(1) · 4,160 · 2,312 · 80%8-K filed 2026-04-30 |
| Dec 31, 2024 | $1.91B | Zepbound(1) · 4,261 · 1,907 · 123% · 13,542 · 4,926 · 175%8-K filed 2026-02-04 |
Revenue volume change
53% for the period ended Sep 30, 2026
The filings read for this page do not define this measure.
| Period ended | Figure | Filing text |
|---|---|---|
| Sep 30, 2026 | 53% | In Q3 2026, worldwide revenue was $24.4 billion, an increase of 39% compared with Q3 2025, driven by a 53% increase in volume, partially offset by a 15% decrease in realized prices.8-K filed 2026-10-29 |
| Jun 30, 2026 | 60% | In Q2 2026, worldwide revenue was $23.0 billion, an increase of 48% compared with Q2 2025, driven by a 60% increase in volume, partially offset by a 13% decrease in realized prices.8-K filed 2026-08-05 |
| Mar 31, 2026 | 65% | In Q1 2026, worldwide revenue was $19.8 billion, an increase of 56% compared with Q1 2025, driven by a 65% increase in volume, partially offset by a 13% decrease due to lower realized prices.8-K filed 2026-04-30 |
| Dec 31, 2025 | 46% | In Q4 2025, worldwide revenue was $19.3 billion, an increase of 43% compared with Q4 2024, driven by a 46% increase in volume, partially offset by a 5% decrease due to lower realized prices.8-K filed 2026-02-04 |
| Sep 30, 2025 | 62% | In Q3 2025, worldwide revenue was $17.60 billion, an increase of 54% compared with Q3 2024, driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices.8-K filed 2025-10-30 |
Reading notes
Figures are shown as first reported. If a later filing prints a different figure for the same period, both appear. A figure marked ≈ or shown in words is how the company itself states it, not an estimate of ours. Companies change definitions over time, so compare periods with the quoted definition in mind. Periods that failed our checks are left out, so gaps are expected.
This page shows the latest 8 periods of each metric.